NextBio

Help
Description: Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Mechanism of Action: Amphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. The drug acts by binding to sterols in the cell membrane of susceptible fungi with a resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles. Amphotericin B, a polyene, binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.
Indication: Used to treat potentially life threatening fungal infections.
Half Life: An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.
View Complete Description




Individual Studies
  • Fetal myoblast differentiation - time course

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    Fetal myoblasts represent an important source of myogenic stem cells. Analysis of undifferentiated myoblasts and comparison to their cognate differentiated progeny will allow the ascertainment of genes that are important for maintaining myogenic stem cells.

    Organization: Ontario Genomics Innovation Centre (OGIC…

  • Yeast resistance to antifungal drugs: fluconazole and amphotericin B

    Saccharomyces cerevisiae Saccharomyces cerevisiae | RNA Expression   RNA Expression

    In this study, replicate populations of Saccharomyces cerevisiae were evolved in increasing concentrations of AmB over hundreds of generations to yield resistant types among which there were permanent changes in gene-expression. Also Three populations at 100 and 400 generations of evolution in in…

    Authors: Anderson B James, Sirjusingh Caroline, Syed Nazia et al.

    Organization: University of Toronto Biology James B. A…

View All Individual Studies

Thought leaders and organizations working on research involving amphotericin b.

  • Nobuaki Matsumori
  • Dimitrios P Kontoyiannis
  • Thomas J Walsh
  • Josep Guarro
  • Tohru Oishi
  • Pfizer
  • Banaras Hindu University
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Pittsburgh
  • Astellas Pharma Inc
  • Innsbruck Medical University
  • Osaka University
  • Universitat Rovira i Virgili
  • University of Houston College of Pharmacy
  • National Cancer Institute

Clinical Trials | 267 trials

Help for Clinical Trials View All

Community

Help for Community
View All NextBio Users | 2 people
  • No NextBio groups were found for “amphotericin b”.
    Be the first to start a group and share your interests with others within the NextBio community.